Microsoft co-founder Allen treated for lymphoma Nov 17, 2009
Seattle-based Vulcan has invested in cancer-drug developers including BiPar Sciences Inc. and Seattle Genetics Inc. The company also owned 30 percent of Metricom Inc., a San Jose, California-based wireless Internet service company, when it filed for bankruptcy in 2001. The remains of Digeo Inc., a closely held maker of digital-video recorders backed by Allen, filed for bankruptcy protection this month. (Sydney Morning Herald -- Business)
Seattle Genetics halts lymphoma drug test Oct 6, 2009
clinical trial resulted in discontinuation of the study, especially given the unmet medical need for DLBCL patients, said Clay Siegall, president and CEO of Seattle Genetics, in a statement. Shares in Seattle Genetics (NASDAQ: SGEN) fell nearly 15 percent in Monday trading, dropping $1. (Puget Sound Business Journal, WA)
Seattle Genetics raising $118.2M Aug 12, 2009
Seattle Genetics stock offering to raise $118 ... Seattle Genetics stock offering to raise $118 ... On Tuesday, Seattle Genetics said it s selling 11 million shares of stock at $10. (Puget Sound Business Journal, WA)
Seattle Genetics plans to raise $100M in stock sale Aug 11, 2009
Seattle Genetics sold 5. 7 million shares of stock and raised $55. (Puget Sound Business Journal, WA)
Seattle Genetics Plans to Sell Shares Aug 11, 2009
Seattle Genetics plans stock sale worth $106 ... Biotechnology company Seattle Genetics Inc. said on Monday it will sell 9 million shares of common stock, with a 30-day option for underwriters to buy another 1. (ABC News -- Wire)
FDA clears Genentech drug for kidney cancer Aug 3, 2009
Seattle Genetics Initiates Brentuximab Vedotin (SGN-35) Retreatment Clinical Trial. Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has initiated a phase II clinical trial of brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC), for the retreatment of patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL) ... D., Chief Medical Officer of Seattle Genetics. (Fresno Bee -- Business)
After Medarex buy, biotech investors ask who's next Jul 24, 2009
NEW YORK (Reuters) Investors bid up shares of Regeneron Pharmaceuticals Inc (REGN.O) and Seattle Genetics Inc (SGEN.O) on Thursday after Medarex Inc (MEDX.O) agreed to be acquired by Bristol-Myers Squibb Co (BMY.N) at a 90 percent premium ... 60 in afternoon trading, while Seattle Genetics was 6 ... Regeneron and Seattle Genetics are the most likely next candidates to be acquired, said Mark Monane, an analyst at Needham p. (Yahoo News -- Pharmaceutical Industry News)
BMY to buy Medarex for $2.4 bn Jul 23, 2009
Other companies that specialize in monoclonal antibodies include Regeneron Pharmaceuticals Inc, Seattle Genetics (SGEN.O), which has multiple collaborations, and Immunogen Inc.. Bristol-Myers said its purchase of Medarex has been unanimously approved by the boards of both companies and is expected to close in late August. (India Times)
Seattle Genetics in deal with Japan firm Apr 7, 2009
Seattle Genetics makes deal with Japanese firm - Puget Sound Business Journal (Seattle) ... Seattle Genetics makes deal with Japanese firm ... Seattle Genetics said it will receive milestone payments and mid-single digit royalties from Millennium on net sales of any resulting ADC products. (Puget Sound Business Journal, WA)
